STUDIO
BioStock Studio: Cyxone comments on the Covid-19 study result
Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data...
RECOMMENDED READING
BioInvent’s CMO on the positive FDA decision
BioInvent has been granted orphan drug status by the U.S. Food and Drug Administration...
PolarCool’s breakthrough year in 2021
In 2021, PolarCool took large strides in its ambition to bring its brain cooling...
